Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion Awards
Argos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)
Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting